oMeds
All answers
Answer · metabolic

Does semaglutide cause muscle loss?

Short answer

GLP-1 therapy drives weight loss that includes both fat and lean mass — typically ~25–40% of total weight lost is lean tissue when no countermeasures are applied. Lean-mass loss is largely preventable with adequate protein intake, resistance training, and provider-reviewed titration; it is a protocol issue, not an inevitability of the molecule.

Reviewed by Dr. Laura PurdyMay 29, 2026

Full answer

All meaningful weight loss — caloric, surgical, or pharmacologic — includes a lean-mass fraction. The published GLP-1 literature places lean-mass loss at roughly 25–40% of total weight lost when patients are not given a structured countermeasure plan. That fraction is not a property of semaglutide specifically; it tracks closely with the rate of total weight loss. The countermeasures are well-established: a protein intake floor (typically 1.2–1.6 g/kg of reference body weight, individualized), resistance training at least 2–3 sessions per week, hydration, and provider-reviewed titration that respects how fast the patient can eat enough protein to defend lean mass. Biomarker context — particularly metabolic markers, kidney function, and body-composition tracking — is part of the same continuity. oMeds' GLP-1 education library (The Nutrition Blueprint, Metabolism Muscle & Body Composition) is structured around this exact question.

Educational. Not a substitute for individualized provider review.

References & sources

Go deeper

Related answers

Is tirzepatide better than semaglutide?
Head-to-head trials show tirzepatide drives larger average weight loss and greater A1C reduction than semaglutide. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a GLP-1 mono-agonist. 'Better' depends on candidacy, tolerance, insurance access, cardiovascular history, and the targeted endpoint — it is a provider-reviewed match, not a universal winner.
Metabolic syndrome criteria?
Metabolic syndrome is a cluster of five cardiometabolic markers — central adiposity, elevated triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose. Diagnosis typically requires three of the five. It is an insulin-resistance-driven state that materially raises cardiovascular and type-2 diabetes risk and is reversible with provider-reviewed metabolic optimization.
What is insulin resistance?
Insulin resistance is a state where cells respond poorly to insulin, so the pancreas secretes more insulin to maintain normal blood glucose. It precedes type-2 diabetes by years and shows up first in fasting insulin, HOMA-IR, triglyceride/HDL ratio, and ApoB before A1C or fasting glucose drift. It is reversible.
Primary source
GLP-1 Standard Library